Clinical efficacy of the combination of indacaterol and glycopyrronium bromide in the treatment of chronic obstructive pulmonary disease at smoking cessation stage

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Therapy of chronic obstructive pulmonary disease (COPD) begins with smoking cessation. An attempt to quit nicotine addiction becomes successful if patient receives adequate bronchodilator therapy.

The aim: to make a comparative analysis of the clinical efficacy of indacaterol and glycopyrronium bromide combination in COPD patients at the stage of smoking cessation.

Material and methods. 111 patients with a high degree of nicotine dependence and irreversible bronchoobstruction were involved in the study. All of them received bronchodilator therapy in accordance with clinical guidelines. The participants were divided into two groups: patients who quit smoking (group 1, n = 53) and patients who continued smoking (group 2, n = 58). In turn, each group was divided into two subgroups depending on the drug used – glycopyrronium bromide 50 mcg or a combination of indacaterol / glycopyrronium bromide (110/50 mcg). Changes in forced expiratory volume in 1 second (FEV1) and the dynamics of COPD assessment test were estimated.

Results. The study revealed an increase of FEV1 and a decrease of COPD assessment test value in both groups. In patients of the 1st group who quit smoking and received a combination of indacaterol and glycopyrronium bromide, the changes had obvious statistically significant differences from the comparison groups (p = 0.0001).

Conclusion. At the stage of smoking cessation in COPD treatment, a combination of indacaterol and glycopyrronium bromide (110/50 mcg) demonstrated high clinical efficacy, which should be recommended to all quitting smoking patients.

全文:

受限制的访问

作者简介

Vitaly Kupaev

Samara State Medical University of the Ministry of Healthcare of Russia

编辑信件的主要联系方式.
Email: vk1964sam@rambler.ru
ORCID iD: 0000-0003-2639-0003

MD, Dr. Sci. (Medicine), professor, head of the Department of family medicine with a course in telemedicine technologies

俄罗斯联邦, Samara

Dmitry A. Osipov

Samara State Medical University of the Ministry of Healthcare of Russia

Email: dmitriylapka@gmail.com
ORCID iD: 0000-0003-0847-7922

MD, postgraduate student of the Department of family medicine with a course in telemedicine technologies

俄罗斯联邦, Samara

参考

  1. Global strategy for the diagnosis, management and prevention of Chronic obstructive pulmonary disease, Global initiative for Chronic Obstructive Lung Disease (GOLD). 2024 report. URL: https://goldcopd.org/wp-content/uploads/2024/02/GOLD-2024_v1.2-11Jan24_WMV.pdf (date of access – 14.08.2024).
  2. Овсянников Е.С., Авдеев С.Н., Будневский А.В. Системное воспаление у больных хронической обструктивной болезнью легких и ожирением. Терапевтический архив. 2020; 92(3): 13–18. [Ovsyannikov E.S., Avdeev S.N., Budnevsky A.V. Systemic inflammation in patients with chronic obstructive pulmonary disease and obesity. Terapevticheskiy arkhiv = Therapeutic Archive. 2020; 92(3): 13–18 (In Russ.)]. https://doi.org/10.26442/00403660.2020.03.000265. EDN: EXZWYY.
  3. Lunze K., Migliorini L. Tobacco control in the Russian Federation – a policy analysis. BMC Public Health. 2013; 13: 64. https://doi.org/10.1186/1471-2458-13-64. PMID: 23339756. PMCID: PMC3732080.
  4. Stead L.F., Koilpillai P., Fanshawe T.R., Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016; 3(3): CD008286. https://doi.org/10.1002/14651858.CD008286.pub3. PMID: 27009521. PMCID: PMC10042551.
  5. Vincken W., Aumann J., Chen H. et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: The GLOW6 study. Int J Chron Obstruct Pulmon Dis. 2014; 9: 215–28. https://doi.org/10.2147/COPD.S51592. PMID: 24596459. PMCID: PMC3940646.
  6. Calverley P.M., Anzueto A.R., Carter K. et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): A double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018; 6(5): 337–44. https://doi.org/10.1016/S2213-2600(18)30102-4. PMID: 29605624.
  7. Barrecheguren M., Monteagudo M., Miravitlles M. Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care. NPJ Prim Care Respir Med. 2018; 28(1): 36. https://doi.org/10.1038/s41533-018-0102-x. PMID: 30266978. PMCID: PMC6162319.
  8. Moita J., Barbara C., Cardoso J. et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther. 2008; 21(1): 146–51. https://doi.org/10.1016/j.pupt.2007.04.003. PMID: 17693107.
  9. Tashkin D.P., Celli B., Kesten S. et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J. 2010; 35(2): 287–94. https://doi.org/10.1183/09031936.00082909. PMID: 19717481.
  10. Tashkin D.P. Goodin Th., Bowling A. et al. Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies. Respir Med. 2019; 155: 113–20. https://doi.org/10.1016/j.rmed.2019.07.019. PMID: 31344660.
  11. Avdeev S., Aisanov Z., Arkhipov V. et al. Withdrawal of inhaled corticosteroids in COPD patients: Rationale and algorithms. Int J Chron Obstruct Pulmon Dis. 2019; 14: 1267–80. https://doi.org/10.2147/COPD.S207775. PMID: 31354256. PMCID: PMC6572750.
  12. Singh D., Agusti A., Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD Science Committee Report 2019. Eur Respir J. 2019; 53(5): 1900164. https://doi.org/10.1183/13993003.00164-2019. PMID: 30846476.
  13. Global strategy for the diagnosis, management and prevention of Chronic obstructive pulmonary disease, Global initiative for Chronic Obstructive Lung Disease (GOLD). 2023 report. URL: https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf (date of access – 14.08.2024).
  14. Arkhipov V., Arkhipova D., Miravitlles M. et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: The SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017; 12: 3255–62. https://doi.org/10.2147/COPD.S142997. PMID: 29138554. PMCID: PMC5680946.
  15. Alter P., Stoleriu C., Kahnert K. et al. Characteristics of current smokers versus former smokers with COPD and their associations with smoking cessation within 4.5 years: Results from COSYCONET. Int J Chron Obstruct Pulmon Dis. 2023; 18: 2911–23. https://doi.org/10.2147/COPD.S436669. PMID: 38084341. PMCID: PMC10710827.
  16. Hashimoto R., Tomioka H., Wada T., Yoshizumi Y. Outcomes and predictive factors for successful smoking cessation therapy in COPD patients with nicotine dependence. Respir Investig. 2020; 58(5): 387–94. https://doi.org/10.1016/j.resinv.2020.03.007. PMID: 32381453.
  17. Pezzuto A., Stellato M., Catania G. et al. Short-term benefit of smoking cessation along with glycopirronium on lung function and respiratory symptoms in mild COPD patients: A retrospective study. J Breath Res. 2018; 12(4): 046007. https://doi.org/10.1088/1752-7163/aad0a8. PMID: 29967309.

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. CAT-test values in the subgroups of the study for the entire observation period

下载 (117KB)
索引源数据
3. Fig. 2. Values of forced expiratory volume in the 1st second in subgroups for the whole period of observation

下载 (90KB)
索引源数据

版权所有 © Bionika Media, 2024
##common.cookie##